VGI Health Technology (XNEC:VTL) Debt-to-Equity : 0.00 (As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Debt-to-Equity?

VGI Health Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's Total Stockholders Equity for the quarter that ended in . 20 was A$0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for VGI Health Technology's Debt-to-Equity or its related term are showing as below:

XNEC:VTL's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

VGI Health Technology Debt-to-Equity Historical Data

The historical data trend for VGI Health Technology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Debt-to-Equity Chart

VGI Health Technology Annual Data

Trend

Debt-to-Equity

VGI Health Technology Semi-Annual Data

Debt-to-Equity

Competitive Comparison of VGI Health Technology's Debt-to-Equity

For the Biotechnology subindustry, VGI Health Technology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Debt-to-Equity falls into.

VGI Health Technology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

VGI Health Technology's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/	N/A
	=	N/A

VGI Health Technology's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/
	=	N/A

VGI Health Technology (XNEC:VTL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

VGI Health Technology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines